Alzamend Neuro, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.alzamend.com

Market Cap $968.39K
Debt $NaN
Cash $1.20M
EV $NaN
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$7.39M
EBIT	-$7.37M
ROA	-442%
Equity	-$1.21M
Growth Stability	1
PE	-0.13
PB	-0.8
Price/Cash	1.24
Equity CAGR	12%
Earnings Growth YoY	-72%
Earnings Growth QoQ	14%

Equity CAGR 5Y	12%
Equity CAGR 3Y	-26%
Market Cap	$968.39K
Assets	$1.67M
Cash	$1.20M
Shares Outstanding	777.82K
Shares Growth 3y	7%
Equity Growth QoQ	-53%
Equity Growth YoY	-1K%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

SEC Filings

Direct access to Alzamend Neuro, Inc. (ALZN) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Jul 31
- 10-K Apr 30
- 10-Q Jan 31
2023
- 10-Q Oct 31
- 10-Q Jul 31
- 10-K Apr 30
- 10-Q Jan 31
2022
- 10-Q Oct 31
- 10-Q Jul 31
- 10-K Apr 30
- 10-Q Jan 31

Sector Comparison

How does Alzamend Neuro, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Alzamend Neuro, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Alzamend Neuro, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Alzamend Neuro, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	04/2020	04/2021	04/2022	04/2023	04/2024	TTM
Net Margins	-	-	-	-	-	-
ROA	-	-170%	-85%	-251%	-2K%	-442%
ROE	-	-251%	-93%	-489%	383%	-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	04/2020	04/2021	04/2022	04/2023	04/2024	TTM
Debt over FCF	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-0.12	-
Growth Stability	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	04/2020	04/2021	04/2022	04/2023	04/2024	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-
Earnings YoY growth	-	14%	145%	20%	-33%	-
Equity YoY growth	-	145%	563%	-77%	-185%	12%
FCF YoY growth	-	-	-	-	-	-